Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy.

Hassan AO, Dmitriev IP, Kashentseva EA, Zhao H, Brough DE, Fremont DH, Curiel DT, Diamond MS.

Cell Rep. 2019 Sep 3;28(10):2634-2646.e4. doi: 10.1016/j.celrep.2019.08.005.

2.

Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.

Stephens CJ, Lauron EJ, Kashentseva E, Lu ZH, Yokoyama WM, Curiel DT.

J Control Release. 2019 Mar 28;298:128-141. doi: 10.1016/j.jconrel.2019.02.009. Epub 2019 Feb 13.

3.

Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.

González-Pastor R, Ashshi AM, El-Shemi AG, Dmitriev IP, Kashentseva EA, Lu ZH, Goedegebuure SP, Podhajcer OL, Curiel DT.

J Ovarian Res. 2019 Feb 15;12(1):18. doi: 10.1186/s13048-019-0493-5.

4.

Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.

Fonseca JA, McCaffery JN, Caceres J, Kashentseva E, Singh B, Dmitriev IP, Curiel DT, Moreno A.

Vaccine. 2018 May 11;36(20):2799-2808. doi: 10.1016/j.vaccine.2018.03.091. Epub 2018 Apr 12.

5.

Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9.

Stephens CJ, Kashentseva E, Everett W, Kaliberova L, Curiel DT.

Gene Ther. 2018 Apr;25(2):139-156. doi: 10.1038/s41434-018-0003-1. Epub 2018 Mar 27.

6.

Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.

Kuroki LM, Jin X, Dmitriev IP, Kashentseva EA, Powell MA, Mutch DG, Dietz AB, Curiel DT, Hawkins WG, Spitzer D.

PLoS One. 2017 Dec 21;12(12):e0190125. doi: 10.1371/journal.pone.0190125. eCollection 2017.

7.

Development of an adenovirus vector vaccine platform for targeting dendritic cells.

Sharma PK, Dmitriev IP, Kashentseva EA, Raes G, Li L, Kim SW, Lu ZH, Arbeit JM, Fleming TP, Kaliberov SA, Goedegebuure SP, Curiel DT, Gillanders WE.

Cancer Gene Ther. 2018 Feb;25(1-2):27-38. doi: 10.1038/s41417-017-0002-1. Epub 2017 Dec 15.

8.

A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.

Fonseca JA, McCaffery JN, Kashentseva E, Singh B, Dmitriev IP, Curiel DT, Moreno A.

Vaccine. 2017 May 31;35(24):3239-3248. doi: 10.1016/j.vaccine.2017.04.062. Epub 2017 May 5.

9.

A One Health overview, facilitating advances in comparative medicine and translational research.

Stroud C, Dmitriev I, Kashentseva E, Bryan JN, Curiel DT, Rindt H, Reinero C, Henry CJ, Bergman PJ, Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y, O'Connor D, Treml LS, Stannard JP, Cook JL, Jacobs M, Wyckoff GJ, Likins L, Sabbagh U, Skaff A, Guloy AS, Hays HD, LeBlanc AK, Coates JR, Katz ML, Lyons LA, Johnson GC, Johnson GS, O'Brien DP, Duan D, Calvet JP, Gandolfi B, Baron DA, Weiss ML, Webster DA, Karanu FN, Robb EJ, Harman RJ.

Clin Transl Med. 2016 Aug;5(Suppl 1):26. doi: 10.1186/s40169-016-0107-4.

10.

A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.

Schmidt DJ, Beamer G, Tremblay JM, Steele JA, Kim HB, Wang Y, Debatis M, Sun X, Kashentseva EA, Dmitriev IP, Curiel DT, Shoemaker CB, Tzipori S.

Clin Vaccine Immunol. 2016 Sep 6;23(9):774-84. doi: 10.1128/CVI.00730-15. Print 2016 Sep.

11.

Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.

Ashshi AM, El-Shemi AG, Dmitriev IP, Kashentseva EA, Curiel DT.

J Ovarian Res. 2016 Jun 27;9(1):38. doi: 10.1186/s13048-016-0248-5.

12.

Erratum: Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.

Tatzel K, Kuroki L, Dmitriev I, Kashentseva E, Curiel DT, Goedegebuure SP, Powell MA, Mutch DG, Hawkins WG, Spitzer D.

Sci Rep. 2016 May 4;6:25217. doi: 10.1038/srep25217. No abstract available.

13.

A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.

Fonseca JA, Cabrera-Mora M, Kashentseva EA, Villegas JP, Fernandez A, Van Pelt A, Dmitriev IP, Curiel DT, Moreno A.

PLoS One. 2016 Apr 29;11(4):e0154819. doi: 10.1371/journal.pone.0154819. eCollection 2016.

14.

Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.

Tatzel K, Kuroki L, Dmitriev I, Kashentseva E, Curiel DT, Goedegebuure SP, Powell MA, Mutch DG, Hawkins WG, Spitzer D.

Sci Rep. 2016 Mar 3;6:22661. doi: 10.1038/srep22661. Erratum in: Sci Rep. 2016 May 04;6:25217.

15.

Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice.

Moayeri M, Tremblay JM, Debatis M, Dmitriev IP, Kashentseva EA, Yeh AJ, Cheung GY, Curiel DT, Leppla S, Shoemaker CB.

Clin Vaccine Immunol. 2016 Jan 6;23(3):213-8. doi: 10.1128/CVI.00611-15.

16.

The N-Terminal Domain of SIRT1 Is a Positive Regulator of Endogenous SIRT1-Dependent Deacetylation and Transcriptional Outputs.

Ghisays F, Brace CS, Yackly SM, Kwon HJ, Mills KF, Kashentseva E, Dmitriev IP, Curiel DT, Imai SI, Ellenberger T.

Cell Rep. 2015 Mar 17;10(10):1665-1673. doi: 10.1016/j.celrep.2015.02.036. Epub 2015 Mar 12.

17.

Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Sheoran AS, Dmitriev IP, Kashentseva EA, Cohen O, Mukherjee J, Debatis M, Shearer J, Tremblay JM, Beamer G, Curiel DT, Shoemaker CB, Tzipori S.

Infect Immun. 2015 Jan;83(1):286-91. doi: 10.1128/IAI.02360-14. Epub 2014 Nov 3.

18.

Monitoring of biodistribution and persistence of conditionally replicative adenovirus in a murine model of ovarian cancer using capsid-incorporated mCherry and expression of human somatostatin receptor subtype 2 gene.

Dmitriev IP, Kashentseva EA, Kim KH, Matthews QL, Krieger SS, Parry JJ, Nguyen KN, Akers WJ, Achilefu S, Rogers BE, Alvarez RD, Curiel DT.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00024.

PMID:
25249483
19.

Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein.

Mukherjee J, Dmitriev I, Debatis M, Tremblay JM, Beamer G, Kashentseva EA, Curiel DT, Shoemaker CB.

PLoS One. 2014 Aug 29;9(8):e106422. doi: 10.1371/journal.pone.0106422. eCollection 2014.

20.

A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, Bae S, Singh KP, Siegal GP, Curiel DT, Alvarez RD.

Gynecol Oncol. 2013 Sep;130(3):518-24. doi: 10.1016/j.ygyno.2013.06.003. Epub 2013 Jun 10.

21.

Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC).

Chen D, Siddiq A, Emdad L, Rajasekaran D, Gredler R, Shen XN, Santhekadur PK, Srivastava J, Robertson CL, Dmitriev I, Kashentseva EA, Curiel DT, Fisher PB, Sarkar D.

Mol Ther. 2013 Apr;21(4):758-66. doi: 10.1038/mt.2012.282. Epub 2013 Jan 15. Erratum in: Mol Ther. 2015 Jul;23(7):1278.

22.

CryoEM visualization of an adenovirus capsid-incorporated HIV antigen.

Flatt JW, Fox TL, Makarova N, Blackwell JL, Dmitriev IP, Kashentseva EA, Curiel DT, Stewart PL.

PLoS One. 2012;7(11):e49607. doi: 10.1371/journal.pone.0049607. Epub 2012 Nov 14.

23.

Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Kashentseva EA, Douglas JT, Zinn KR, Curiel DT, Dmitriev IP.

J Mol Biol. 2009 May 8;388(3):443-61. doi: 10.1016/j.jmb.2009.03.016. Epub 2009 Mar 13.

24.

Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid.

San Martín C, Glasgow JN, Borovjagin A, Beatty MS, Kashentseva EA, Curiel DT, Marabini R, Dmitriev IP.

J Mol Biol. 2008 Nov 21;383(4):923-34. doi: 10.1016/j.jmb.2008.08.054. Epub 2008 Aug 29.

25.

FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.

Li FJ, Ding S, Pan J, Shakhmatov MA, Kashentseva E, Wu J, Li Y, Soong SJ, Chiorazzi N, Davis RS.

Blood. 2008 Jul 1;112(1):179-87. doi: 10.1182/blood-2008-01-131359. Epub 2008 Feb 26.

26.

Identification of sites in adenovirus hexon for foreign peptide incorporation.

Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, Dmitriev I, Kataram M, Mahasreshti PJ, Curiel DT.

J Virol. 2005 Mar;79(6):3382-90.

27.

Noninvasive of adenovirus tumor retargeting in living subjects by a soluble adenovirus receptor-epidermal growth factor (sCAR-EGF) fusion protein.

Liang Q, Dmitriev I, Kashentseva E, Curiel DT, Herschman HR.

Mol Imaging Biol. 2004 Nov-Dec;6(6):385-94.

PMID:
15564149
28.

Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy.

Wu H, Han T, Lam JT, Leath CA, Dmitriev I, Kashentseva E, Barnes MN, Alvarez RD, Curiel DT.

Gene Ther. 2004 May;11(10):874-8.

PMID:
14999229
29.

Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob.

Uil TG, Seki T, Dmitriev I, Kashentseva E, Douglas JT, Rots MG, Middeldorp JM, Curiel DT.

Cancer Gene Ther. 2003 Feb;10(2):121-4.

PMID:
12536200
30.

Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT.

J Virol. 2002 Dec;76(24):12775-82.

31.

Addition of six-His-tagged peptide to the C terminus of adeno-associated virus VP3 does not affect viral tropism or production.

Zhang HG, Xie J, Dmitriev I, Kashentseva E, Curiel DT, Hsu HC, Mountz JD.

J Virol. 2002 Dec;76(23):12023-31.

32.

Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency.

Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, Han T, Curiel DT.

Hum Gene Ther. 2002 Sep 1;13(13):1647-53.

PMID:
12228019
33.

Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells.

Pereboev AV, Asiedu CK, Kawakami Y, Dong SS, Blackwell JL, Kashentseva EA, Triozzi PL, Aldrich WA, Curiel DT, Thomas JM, Dmitriev IP.

Gene Ther. 2002 Sep;9(17):1189-93.

34.

Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo.

Seki T, Dmitriev I, Suzuki K, Kashentseva E, Takayama K, Rots M, Uil T, Wu H, Wang M, Curiel DT.

Gene Ther. 2002 Aug;9(16):1101-8.

35.
36.
37.

Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines.

Seki T, Dmitriev I, Kashentseva E, Takayama K, Rots M, Suzuki K, Curiel DT.

J Virol. 2002 Feb;76(3):1100-8.

38.

Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors.

Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, Li H, Parameshwar M, Vickers SM, Jaffee EM, Huibregtse K, Curiel DT, Dmitriev I.

Gene Ther. 2001 Jul;8(13):969-76.

39.

Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity.

Krasnykh V, Dmitriev I, Navarro JG, Belousova N, Kashentseva E, Xiang J, Douglas JT, Curiel DT.

Cancer Res. 2000 Dec 15;60(24):6784-7. Review.

41.

[Isolation and study of recombinant strains of Salmonella typhimurium SL 7207, producing HBcAG and HBcAG-HBs].

Karpenko LI, Ignat'ev GM, Kozhina EM, Kashentseva EA, Poryvaeva VA, Melamed NV, Baĭborodin SI, Smirnova OIu, Il'ichev AA.

Vopr Virusol. 2000 Mar-Apr;45(2):10-4. Russian.

PMID:
10765543
42.

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism.

Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT.

J Virol. 1998 Dec;72(12):9706-13.

43.

[Induction of immune mediators in human cultured mononuclear cells by Marburg virus].

Ignat'ev GM, Strel'tsova MA, Kashentseva EA.

Vopr Virusol. 1998 Jul-Aug;43(4):169-73. Russian.

PMID:
9791882
44.

[Effects of tumor necrosis factor antiserum of the course of Marburg hemorrhagic fever].

Ignat'ev GM, Strel'tsova MA, Kashentseva EA, Patrushev NA.

Vestn Ross Akad Med Nauk. 1998;(3):35-8. Russian.

PMID:
9608275
45.

[Immunologic indicators in vaccinated mice with Machupo virus infection].

Patrusheva IV, Kaliberov SA, Kashentseva EA, Ignat'ev GM.

Vopr Virusol. 1997 May-Jun;42(3):137-40. Russian.

PMID:
9297347
46.

[Experimental study of possible treatment of Marburg hemorrhagic fever with desferal, ribavirin, and homologous interferon].

Ignat'ev GM, Strel'tsova MA, Agafonov AP, Kashentseva EA, Prozorovskiĭ NS.

Vopr Virusol. 1996 Sep-Oct;41(5):206-9. Russian.

PMID:
8967064
47.

[Experimental study of the effect of the drug desferal and serum against tumor necrosis factor on the course of the infectious process in arenaviral hemorrhagic fever].

Ignat'ev GM, Kashentseva EA, Kaliberov SA, Prozorovskiĭ NS.

Antibiot Khimioter. 1996 Feb;41(2):30-4. Russian. No abstract available.

PMID:
8929116
48.

Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys.

Ignatyev GM, Agafonov AP, Streltsova MA, Kashentseva EA.

J Biotechnol. 1996 Jan 26;44(1-3):111-8.

PMID:
8717394
49.

[Experimental study of the possibility of emergency prophylaxis of Bolivian hemorrhagic fever].

Kaliberov SA, Ignat'ev GM, Pereboeva LA, Kashentseva EA.

Vopr Virusol. 1995 Sep-Oct;40(5):211-5. Russian.

PMID:
8659175
50.

[Mechanisms of protective immune response in models of Marburg fever in monkeys].

Ignat'ev GM, Strel'tsova MA, Agafonov AP, Kashentseva EA.

Vopr Virusol. 1995 May-Jun;40(3):109-13. Russian.

PMID:
7676670

Supplemental Content

Loading ...
Support Center